Invested in the Future of Cardiovascular Medicine

Our purpose is driven by our vision to stop cardiovascular disease from being a leading cause of death worldwide. Amarin is a global pharmaceutical company developing new treatments to fight against cardiovascular disease. Amarin is relentless in its pursuit of scientific breakthroughs that can lead to revolutionary treatments to create a healthier world. Find out more about who we are, what we stand for and how we are making a difference in the lives of patients.

Show all

Quarterly Earnings Q2 2026

Learn more

Latest Events

Click a link below for access to our events.

Learn more

Latest News From Amarin

From research results, financial toolkits and webcasts to important investor information and financial governance. Find out the latest financial news about Amarin in these publications.

Learn More

Oct 25, 2026

Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)

Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The   Key Secondary Endpoint of OS Was Improved With VAZKEPA/VASCEPA Patients Taking VASCEPA Prior to and Following Liver Resection
Read more
Oct 21, 2026

Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026

DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report third quarter 2026 financial results and conduct a conference call on Wednesday,
Read more
Aug 31, 2026

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/ European Renal Association (ERA) Cardiova scular and Chronic Kidney Disease Guideline Further Reinforces the
Read more

Investor inquiries

For corporate governance, analyst coverage, stock information, secretarial matters and other investor-related queries, please use the Contact form:

Contact Us
Financial Information

Balancing Passion with Resolution

Learn more about Amarin’s revenue, expenses, profit and loss, as well as a comprehensive overview of the company’s financial health.

Learn More

 

Sign-Up for Email Alerts

Amarin Logo
You are about to leave the Amarincorp.com website
You have selected a link that will take you away from the amarincorp.com website. Amarin is not responsible for the content of the alternate website. Privacy and security policies of the alternate website may differ from those practiced by Amarin.

By clicking on the continue button below, you acknowledge the previous statement and will be taken to the linked site. If you want to remain at this site, select the cancel button. Thank you.